(0.25%) 5 321.41 points
(0.17%) 39 873 points
(0.22%) 16 833 points
(-0.25%) $79.06
(-0.15%) $2.67
(-0.02%) $2 425.50
(0.61%) $32.28
(0.06%) $1 061.50
(0.01%) $0.921
(0.08%) $10.67
(0.00%) $0.787
(0.29%) $90.49
@ $2.43
Utstedt: 12 feb 2024 @ 21:26
Avkastning: -21.81%
Forrige signal: feb 6 - 20:26
Forrige signal:
Avkastning: 0.00 %
Live Chart Being Loaded With Signals
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...
Stats | |
---|---|
Dagens volum | 41 591.00 |
Gjennomsnittsvolum | 1.48M |
Markedsverdi | 5.43M |
EPS | $0 ( 2024-05-20 ) |
Neste inntjeningsdato | ( $-0.980 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.220 |
ATR14 | $0.0170 (0.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-01 | Young David | Buy | 1 675 | Common Stock |
2024-01-01 | Young David | Sell | 518 | Common Stock |
2024-01-01 | Young David | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Buy | 1 675 | Common Stock |
INSIDER POWER |
---|
80.51 |
Last 99 transactions |
Buy: 3 005 145 | Sell: 402 801 |
Volum Korrelasjon
Processa Pharmaceuticals, Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
VTNR | 0.928 |
UXIN | 0.926 |
VRM | 0.924 |
PLL | 0.92 |
AXDX | 0.912 |
RNAZ | 0.91 |
CNSP | 0.904 |
MHUA | 0.897 |
IRBT | 0.896 |
SNAX | 0.893 |
10 Mest negative korrelasjoner | |
---|---|
FFNW | -0.912 |
HQY | -0.886 |
ADTH | -0.881 |
SFBC | -0.875 |
FGFPP | -0.867 |
ISRG | -0.859 |
AGNCP | -0.854 |
FSEA | -0.849 |
PRAX | -0.847 |
SRPT | -0.845 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Processa Pharmaceuticals, Korrelasjon - Valuta/Råvare
Processa Pharmaceuticals, Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-27.53M (0.00 %) |
EPS: | $-68.10 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Processa Pharmaceuticals,
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.